General Information of Drug (ID: DMR5D16)

Drug Name
N-(4-amino-4'-fluorobiphenyl-3-yl)benzamide Drug Info
Synonyms CHEMBL1098337; SCHEMBL15398027; BDBM50317988
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
46830345
TTD Drug ID
DMR5D16

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
CHR-3996 DMIXPNG Lymphoma 2A80-2A86 Phase 1/2 [2]
PMID29671355-Compound-62 DMWRS34 N. A. N. A. Patented [3]
PMID29671355-Compound-43 DMVPMWJ N. A. N. A. Patented [3]
PMID29671355-Compound-25 DMPV0KZ N. A. N. A. Patented [3]
PMID29671355-Compound-21 DMPJN0M N. A. N. A. Patented [3]
PMID29671355-Compound-31 DM3H78D N. A. N. A. Patented [3]
PMID29671355-Compound-56 DM0VBMI N. A. N. A. Patented [3]
PMID29671355-Compound-67 DM1RPL4 N. A. N. A. Patented [3]
PMID29671355-Compound-23 DMUBOEX N. A. N. A. Patented [3]
PMID29671355-Compound-44 DM80A3V N. A. N. A. Patented [3]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Histone deacetylase 2 (HDAC2) TTSHTOI HDAC2_HUMAN Inhibitor [1]

References

1 Exploration of the HDAC2 foot pocket: Synthesis and SAR of substituted N-(2-aminophenyl)benzamides. Bioorg Med Chem Lett. 2010 May 15;20(10):3142-5.
2 A phase I pharmacokinetic and pharmacodynamic study of CHR-3996, an oral class I selective histone deacetylase inhibitor in refractory solid tumors. Clin Cancer Res. 2012 May 1;18(9):2687-94.
3 HDAC inhibitors: a 2013-2017 patent survey.Expert Opin Ther Pat. 2018 Apr 19:1-17.